- Conditions
- Solid Tumor, Adult, Malignant Solid Tumor, Stomach Adenocarcinoma, Esophageal Adenocarcinoma
- Interventions
- Tremelimumab, Durvalumab
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Orange, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatobiliary Cancers
- Interventions
- Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
- Conditions
- Advanced and/or Metastatic Sarcoma
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mesothelioma
- Interventions
- Tremelimumab, Durvalumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Buffalo, New York • New York, New York
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 14 more
- Conditions
- Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
- Interventions
- AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- MEDI4736, tremelimumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 16 more
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Durvalumab, Tremelimumab, SGI-110
- Drug
- Lead sponsor
- Catherine Shu
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- MEDI4736 monotherapy, tremelimumab+MEDI4736
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Moshe Ornstein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Cleveland, Ohio
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer
- Interventions
- durvalumab and tremelimumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed therapy, Durvalumab
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- MEDI4736, tremelimumab, AZD9150
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- La Jolla, California • Baltimore, Maryland • Albuquerque, New Mexico + 5 more
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Interventions
- Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab
- Biological · Procedure · Other + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
- Interventions
- Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab
- Biological · Radiation
- Lead sponsor
- Mary Feng, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Solid Tumors
- Interventions
- mogamulizumab, MEDI4736 (Durvalumab), tremelimumab
- Biological
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 7
- States / cities
- Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 3 more
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- durvalumab, Tremelimumab
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 18
- States / cities
- Duarte, California • New Haven, Connecticut • North Haven, Connecticut + 11 more
- Conditions
- Bladder Cancer
- Interventions
- Tremelimumab, Durvalumab, Bladder radiation, Intravesicular Therapy
- Drug · Radiation
- Lead sponsor
- Daniel George, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
- Interventions
- Durvalumab, External Beam Radiation Therapy, Tremelimumab
- Biological · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Durvalumab, Tremelimumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas